Bottom line. MCK reported a solid F1Q27 (calendar 2Q26) beat. However, the post-print reaction was tempered amid an EPS guidance raise that was effectively the same amount as the beat, keeping expectations for F2Q27–F4Q27 in line with pre-print consensus. Adjusted EPS of $9.93 beat consensus by $0.37, or 3.9%, while adjusted operating income of $1.653B came in 5.3% above consensus. Revenue beat by 1.4%. North American Pharmaceutical and Oncology & Multispecialty supplied the upside, while Medical-Surgical missed sharply. FY27 adjusted EPS guidance was raised by $0.40, only $0.03 more than the F1Q27 beat. Regardless, the result strengthens the case for McKesson’s specialty-led operating model, and keeps the stock and fundamental story on track for now. While the read is moderately constructive on the business, the stock’s premium valuation will continue to demand strong execution and more earnings upside in future quarters.
Distribution economics carried the beat
The North American Pharmaceutical segment was the strongest driver of the beat. Revenue of $86.773B was 0.8% below consensus, as January WAC reductions and branded-to-generic conversions weighed on reported top-line growth. Adjusted operating profit, however, rose 19% to $894M, 10.8% above consensus, and margin expanded by 12 bps to 1.03%. Management clarified two items: (1) lower WAC reduced reported revenue but had little effect on profit because McKesson recognizes branded-drug revenue at the drug’s selling price, while more than 95% of its branded-drug contracts compensate it on a fee-for-service basis; (2) branded-to-generic conversions benefited gross profit, despite reducing reported revenue. Specialty distribution to health systems and strategic accounts, along with new-product-launch timing, also drove the year-over-year profit increase. GLP-1 distribution revenue reached $15B, up 24% year-over-year; they did not disclose GLP-1 profit growth. The best characterization of the segment’s quarter is that lower WAC and branded-to-generic conversions obscured the top-line result, while specialty volume, favorable launch timing and the gross-profit benefit from those conversions drove the operating profit beat.
The Oncology & Multispecialty segment also supported the beat. Revenue grew 33% to $14.222B and adjusted profit rose 41% to $405M, 6.6% above consensus; excluding Core Ventures, management estimated growth of roughly 24% and 15%, respectively. The Prescription Technology Solutions segment was healthy but less incremental: revenue and adjusted profit rose 9% and 13% to $1.566B and $303M, with profit exactly in line with consensus. In dollar terms, North American Pharmaceutical and Oncology & Multispecialty contributed $263M of the $229M year-over-year increase in consolidated adjusted operating income, before Medical-Surgical and other offsets.
Sources: McKesson; StreetAccount; Graver Research calculations.
The raise mostly banked the F1Q27 beat
The full-year EPS bridge is where the constructive read needs to be tempered. Prior to the report, FY27 and F1Q27 adjusted EPS consensus sat at $44.26 and $9.56, respectively. That implied F2Q27–F4Q27 pre-print adjusted EPS consensus at $34.70, while the updated guidance midpoint implies $34.67 of adjusted EPS for F2Q27–F4Q27. That leaves a straightforward implication: the $0.40 range increase largely banked the $0.37 F1Q27 beat. Management may still outperform, but the raise itself did not establish a higher F2Q27–F4Q27 earnings path.
Management’s full-year segment outlook embeds the same pattern. For NAP and Oncology the outlook assumes a much slower pace of growth after their unusually strong F1Q27 results, while the RxTS outlook assumes steady growth, and Medical-Surgical assumes a recovery. If NAP finishes at the high end of its profit-growth range, its combined F2Q27–F4Q27 profit would need to grow about 6.8% year-over-year, versus 19.4% in F1Q27. Using the midpoint elsewhere, Oncology’s remaining-year growth is approximately 9.1% after 41.1% in F1Q27, although acquisition timing makes that comparison less indicative of underlying momentum. RxTS remains near its F1Q27 pace, while Medical-Surgical must swing from a 20.1% decline in F1Q27 to roughly 8.9% growth over the remaining three quarters. Those calculations fit with management’s explanation that some generic and launch favorability arrived early, while higher investment in growth and AI is concentrated in the second half.
Sources: McKesson Q4 FY26 and Q1 FY27 earnings releases and Q1 FY27 earnings presentation; Graver Research calculations.
McKesson raised consolidated adjusted operating-profit growth guidance to 9%–13% from 8%–12% and now expects NAP to finish at the high end of its 5.5%–9.5% range. The gap between NAP’s 19.4% F1Q27 growth and its 6.8% F2Q27–F4Q27 hurdle leaves room for a meaningful slowdown if specialty demand moderates or F1Q27’s timing favorability creates a larger second-half payback. Higher second-half investment is already embedded in the full-year outlook, while the 50 bps increase in the midpoint of the tax-rate range limits how much of the improved operating outlook reaches EPS. Guidance may still prove conservative, but the raise itself did not prove that; F2Q27–F4Q27 delivery must do that.
Medical-Surgical and cash remain the exceptions
The Medical-Surgical segment is the clearest reason not to call the quarter uniformly high quality. Revenue rose 4% to $2.819B and modestly exceeded consensus, but adjusted profit fell 20% to $195M, 21.1% below the $247.1M pre-print consensus, and drove a 211 bps margin decline to 6.92%. Management attributed the weakness to product mix and one-time administrative expenses, partly offset by extended-care growth. That explanation may be right, but the unchanged flat-to-4% full-year profit outlook now requires roughly 8.9% growth over F2Q27–F4Q27 at the midpoint. The segment remains in consolidated results while the Wellverse separation advances, so its margin recovery still matters to near-term earnings quality.
The GAAP bridge was also unusually large. GAAP EPS of $5.15 was $4.78 below adjusted EPS, largely due to transaction and separation accounting. The $3.85 per-share transaction adjustment included a $293M remeasurement of Apollo’s redeemable minority interest; restructuring/impairment and amortization added another $0.82 and $0.41. But operations still led the adjusted result. McKesson attributed $1.41 of the $1.67 year-over-year increase to operating performance, versus $0.50 to capital allocation and a $0.24 drag from other items. Buybacks supplied about 30% of growth, material but secondary.
Cash conversion improved, but still remains a key nit-to-pick. F1Q27 free cash flow was negative $372M, versus negative $1.107B a year earlier, as working-capital execution improved. Management correctly noted that McKesson’s fiscal first quarter is seasonally negative and said much of the change was structural. But FY27 free-cash-flow guidance stayed at $4.5B-$4.9B. The $4.7B midpoint is about 13% below FY26’s $5.410B result even as adjusted EPS is expected to grow 15%-17% from the company’s normalized base. One better seasonal quarter lowers the concern at the margin. A raised full-year cash outlook or sustained working-capital improvement would do more to validate the earnings path.
The stock moved more than the estimates
MCK had already risen 5.6% to $877.23 on August 5 before its after-market-close report, likely helped by a positive read-through from Cencora’s before-market-open earnings beat and guidance raise; COR gained 3.6% that day. In the first post-print session, MCK shares opened another 4.0% higher but closed at $871.38, down 0.7% from the prior close. By August 21, MCK was at $858.90: down 2.1% from the August 5 baseline but still 3.4% above August 4. Over the same August 4-August 21 window, FY27 EPS consensus rose $0.37 to $44.63 and FY28 moved only $0.18 to $50.56. At 18.4x NTM EPS, versus a 10-year median of 12.5x and a +1 standard-deviation level of 17.0x, the stock already requires more than a good F1Q27 report.
Sources: Koyfin price and consensus histories; McKesson and Cencora earnings releases; StreetAccount; Graver Research analysis.
The next proof is outer-quarter delivery
The F1Q27 report showed solid growth in distribution profit while WAC reductions pressured recognized revenue, with Oncology providing a second operating engine, RxTS remaining solid, and the portfolio overcoming weakness in Medical-Surgical. However, it was helped by early generic and launch benefits, and left the implied F2Q27–F4Q27 EPS path essentially unchanged from pre-print consensus. The most useful next test is measurable: NAP needs to meet or beat the roughly 6.8% implied F2Q27–F4Q27 profit path without another pull-forward, Medical-Surgical needs to show the recovery embedded in guidance, and FY27 cash flow and FY28 estimates need to move with earnings. A raised cash outlook, sustained outer-year revisions and cleaner Medical-Surgical revenue-to-profit conversion would strengthen the interpretation. More timing benefits, another segment miss or a buyback-led beat would leave it roughly where it stands. For now, the operating case improved more than the forward earnings case.